No Data
No Data
Maiwei Biological (688062.SH): 9MW2821 is included in the breakthrough therapy for the indication of urothelial carcinoma.
Meiwei Bio (688062.SH) announced that the company has developed the innovative drug 9MW2821 through independent intellectual property rights research and development...
Mabwell Shanghai Bioscience's Unit Buys Rights for Runjia Pharmaceutical's Osteoarthritis Drug
Is Mabwell (Shanghai) Bioscience (SHSE:688062) Using Too Much Debt?
Express News | FDA Grants Orphan Drug Designation to 7MW3711
Express News | Mabwell Receives Nmpa Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in Tnbc
Express News | FDA Grants Fast Track Designation to 9MW2821 for the Treatment of Patients With Locally Advanced or Metastatic Nectin-4 Positive Tnbc
No Data